In:
mBio, American Society for Microbiology, Vol. 8, No. 5 ( 2017-11-08)
Kurzfassung:
Recent studies suggest that low-dose DNA-damaging compounds traditionally used in cancer therapy can have opposite effects on antiviral responses, either suppressing (with the example of CPT) or potentiating (with the example of doxorubicin) them. Our work demonstrates that the minor DNA damage promoted by low-dose CPT can also trigger strong antiviral responses, dependent on the presence of viral oncogenes. Taken together, these results call for caution in the therapeutic use of low-dose chemotherapy agents to modulate antiviral responses in humans.
Materialart:
Online-Ressource
ISSN:
2161-2129
,
2150-7511
DOI:
10.1128/mBio.01611-17
Sprache:
Englisch
Verlag:
American Society for Microbiology
Publikationsdatum:
2017
ZDB Id:
2557172-2
